These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35670702)

  • 1. Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.
    Wang X; Zhang J; Han B
    Adv Anat Pathol; 2022 Jul; 29(4):252-258. PubMed ID: 35670702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
    Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
    Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
    Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant hormonal therapy in carcinoma of the prostate.
    Lee HH; Warde P; Jewett MA
    BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
    Naiki T; Kawai N; Okamura T; Nagata D; Kojima Y; Akita H; Yasui T; Tozawa K; Kohri K
    BMC Urol; 2012 Dec; 12():36. PubMed ID: 23249358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
    Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
    Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
    Civantos F
    Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
    Tafuri A; Cerruto MA; Antonelli A
    Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy.
    Sun L; Xu T; Yuan X; Liu F; Guan F; Ye D; Zhang G
    Tumori; 2020 Apr; 106(2):133-138. PubMed ID: 31451070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.
    Bono AV; Pagano F; Montironi R; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Selli C; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Diamanti L; Santinelli A; Mazzucchelli R; Prayer-Galletti T;
    Urology; 2001 Jan; 57(1):117-21. PubMed ID: 11164155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.